Interim Report July - September 2018
“Broad based progress”Summary of Q3 Financial overview July 1 – September 30 2018 · Net sales amounted to SEK 0.0 M (0.0) · Loss for the period was SEK 103.0 M (loss: 51.6) · Loss per share, before and after dilution, was 2.34 (loss: 1.30) SEK · On September 30 cash and cash equivalents amounted to SEK 488.9 M (443.0) Significant events during the period July 1 to September 30 2018 · During September, the first patient-initiated treatment in Oncopeptides’ Phase II-study BRIDGE with Ygalo® in RRMM patients with renal impairment · Anders Martin-Löf appointed as